Healthcare / BiotechnologyTel Aviv
$38.40
-0.50 (-1.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-21.7M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$448M
P/E
N/A
•EV/EBITDA
N/A
•ROE
432.4%
↑Gross Margin
N/A
•Debt/Equity
-1.57
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-24.5M · FCF $-14.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-24.5M | $-24.5M | $-27.8M | $-28.5M | $-38.7M |
| EBITDA | $-21.0M | $-21.0M | $-24.3M | $-24.9M | $-35.1M |
| EPS | — | — | -0.04 | -0.05 | -0.06 |
| Balance Sheet | |||||
| Debt/Equity | -1.57 | -1.57 | 1.46 | 0.38 | 0.21 |
| Current Ratio | 0.13 | 0.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-14.9M | $-14.9M | $-21.7M | $-27.2M | $-35.2M |
| Returns | |||||
| ROE | 432.4% | 432.4% | -400.0% | -97.4% | -68.6% |
| Valuation | |||||
| P/B | — | — | 1418.13 | 404.14 | 260.81 |
| Growth & Yield | |||||
| EPS Growth | — | — | 20.0% | 16.7% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+134.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → n/d
Residual
+134.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.